Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease

Autoimmunity

Volumn 43, Issue 8, 2010, Pages 698-703

  De Haan, Sofie ^a   Lahooti, Hooshang ^a   Morris, Olivia ^b   Wall, Jack R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

autoimmunity; calsequestrin; eye muscle; Graves' disease; thyroid eye disease

Indexed keywords

AUTOANTIBODY; CALSEQUESTRIN; CALSEQUESTRIN 1 ANTIBODY; CALSEQUESTRIN 2 ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; CALCIUM-BINDING PROTEINS; CALSEQUESTRIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; GRAVES OPHTHALMOPATHY; HASHIMOTO DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS;

EID: 78149448141     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003774954     Document Type: Article

References (34)

1. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002;12:855-860.
2. Burch HB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793.
3. Tjiang H, Lahooti H, McCorquodale T, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto's thyroiditis. Thyroid 2010;20:287-290.
4. Lahooti H, Parmar KR, Wall JR. Pathogenesis of thyroid eye disease: Important role ofautoimmunity against calsequestrin and collagen XIII. A review. Clin Ophth 2010;14:417-425.
5. Weetman AP. Graves' disease. N Engl J Med 2000;343: 1236-1248.
6. Tani J, Wall JR. Analysis\Can the development of thyroid-associated ophthalmopathy be explained by autoimmunity against eye muscle antigens? Can Med Assoc J 2006;17: 239-241.
7. Tani J, Gopinath B, Nuygen B, Wall JR. Immunological mechanisms for the eye muscle and orbital connective tissue reactions of thyroid-associated ophthalmopathy. Expert Rev Clin Immunol 2007;3:299-311.
8. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91: 3464-3470.
9. Bahn RS. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003;88:1939-1946.
10. Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy Clin Endocrinol (Oxf) 1995;42:565-569.
11. Wall JR. The TSH-receptor and thyroid-associated ophthal-mopathy\A convenient hypothesis with too many exceptions to be true. Int J Endocrinol Metab 2007;2:49-51.
12. Kubota S, Gunji K, Ackrell AC, Cochran B, Stolarski C, Wengrowicz S, Kennerdell JS, Hiromatsu Y, Wall JR. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: The corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998;83:443-447.
13. Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell BA, Salvi M, Bellastella A, Bizzarro A, Sinisi AA, Wall JR. Serum antibodies against the flavoprotein subunit ofsuccinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroid-ism. J Clin Endocrinol Metab 1999;84:1255-1262.
14. Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29:1-9.
15. Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T. Type III collagen is identified as a plasma membrane protein. J Biol Chem 1998;273:15590-15597.
16. De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A. Serum antibodies to collagen XIII: A further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005;62:24-29.
17. Gopinath B, Musselman R, Beard N, Tani J, Adams C, Wall JR. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are sensitive and specific markers of ocular myopathy in patients with Graves' disease. Clin Exp Immunol 2006;145:56-62.
18. Gopinath B, Musselman R, Adams C, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmo-pathy-correlation with clinical features. Thyroid 2006;16: 967-974.
19. Gopinath B, Adams CL, Musselman R, Tani J, Wall JR. Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid lag and retraction. Ocul Immunol Inflamm 2007;15:81-88.
20. Gopinath B, Tani J, Bao N, Wall JR. Eye muscle and collagen XIII antibodies and eye signs in patients with transient and chronic thyroiditis. Thyroid 2007;17:1-7.
21. Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Biophys Mol Biol 2004;85:33-69.
22. Park H, Park IY, Kim E, Youn B, Fields K, Dunker AK, Kang C. Comparing skeletal and cardiac calsequestrin structures and their calcium binding: A proposed mechanism for coupled calcium binding and protein polymerization. J Biol Chem 2004;279:18026-18033.
23. Fliegel L, Burns K, Wlasichuk K, Michalak M. Peripheral membrane proteins of sarcoplasmic and endoplasmic reticu-lum. Comparison ofcarboxyl-terminal amino acid sequences. Biochem Cell Biol 1989;67:696-702.
24. Scott BT, Simmerman HK, Collins JH, Nadal-Ginard B, Jones LR. Complete amino acid sequence of canine cardiac calsequestrin decuded by cDNA cloning. J Biol Chem 1988; 263:8958-8964.
25. Slupsky JR, Ohnishi M, Carpenter MR, Reithmeier RA. Characteristics ofcardiac calsequestrin. Biochemistry 1987; 26:6539-6544.
26. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Andrade FH. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001;98:12062-12067.
27. Wescombe L, Gopinath B, Lahooti H, Wall JR. The cardiac calsequestrin gene (CASQ2) is up-regulated in the thyroid in patients with Graves' ophthalmopathy-support for a role of autoimmunity against calsequestrin as the triggering event. Clin Endocrinol (Oxf) 2010 [ePub ahead of print].
28. Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstr Surg 1993;9:77-82.
29. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management ofpatients with Graves' Ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47:9-14.
30. Werner SC. Classification of the eye changes of Graves' disease. Am J Ophthalmol 1969;68:646-648.
31. Rahbar A, Boström L, Söderberg-Naucler C. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J Autoimmunity 2006;26:155-164.
32. Abehsira O, Edwards A, Simpson E. Functional and binding activity of monoclonal anti-Thy-1 antibodies: Evidence for differentexpressionofthetwoalleles. Eur J Immunol 1981;11: 275-281.
33. Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 1990;9:S16.
34. Flanagen JG, Rabbits TH. Arrangement of human immuno-globulin heavy chain constant region genes implies evolution-ary duplication of a segment containing gamma, epsilon and alpha genes. Nature 1982;300:709-713.